Key Highlights

  • The FDA accepted for review Alvotech's Biologics License Application for AVT80, a proposed interchangeable biosimilar to Entyvio.
  • Alvotech announced a licensing deal with Lotus Pharmaceutical for AVT34 and AVT87 covering U.S. and Asian markets, valued at roughly $150 million.
  • The company has resubmitted BLAs for AVT05 and AVT06, with FDA decisions expected in the fourth quarter of 2026.

Alvotech (NASDAQ: ALVO) is a rare pure-play bet on biosimilars, the lower-cost copies of complex biologic medicines that are reshaping how health systems manage spending. After a stretch of range-bound trading, the stock's next decisive move may hinge less on day-to-day sentiment and more on a cluster of regulatory decisions and commercial deals stacking up in the second half of 2026. For a company built on getting products approved and launched, the pipeline calendar is the story.

Company and Latest Development

Incorporated in Luxembourg and Manufacturing in Reykjavik, Iceland, Alvotech develops and produces Biosimilars that global partners commercialize, and it already has several approved products on the market. In late August 2026 the company said the U.S. Food and Drug Administration accepted for review its Biologics License Application for AVT80, a proposed interchangeable biosimilar to Entyvio (vedolizumab) in subcutaneous prefilled-syringe and autoinjector formats, a program partnered with Teva. Days earlier, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical covering the biosimilar candidates AVT34 (durvalumab) and AVT87 (emicizumab) for the U.S. and Asian markets, a deal it valued at roughly $150 million in upfront and milestone payments.

What Is Driving Attention Around ALVO?

With the shares holding steady, the question is what breaks the range. The clearest answers are regulatory. Alvotech has resubmitted BLAs for AVT05, a biosimilar to Simponi (golimumab), and AVT06, a biosimilar to Eylea (aflibercept), with FDA decisions expected in the fourth quarter of 2026. Those rulings, together with progress on the newly accepted AVT80 filing, are the kind of binary events that can reset expectations. A flat tape does not require a catalyst, but the pipeline offers several plausible ones.

Key Numbers and Company Position

For the first half of 2026, Alvotech reported adjusted Revenue of $211.9 million, down from $306.1 million a year earlier, with adjusted EBITDA of $46.9 million and a cash position of $142.8 million. The company guided to full-year 2026 revenue of $650 million to $700 million and adjusted EBITDA of $180 million to $220 million, implying a stronger second half. The Lotus agreement adds up to about $150 million in potential upfront and milestone payments, with Alvotech retaining U.S. co-commercialization rights and acting as exclusive global supplier. The company carries a market Capitalization of roughly $2 billion.

What Could Come Next?

The fourth-quarter FDA decisions on AVT05 and AVT06 are the marquee upcoming catalysts, and each approval would expand the commercial portfolio. Advancement of the AVT80 Entyvio program, execution on the Teva and Lotus partnerships, and the path toward meeting full-year guidance are additional items to monitor. Given the implied second-half acceleration, quarterly delivery against targets will be closely scrutinized.

Risks to Watch

Biosimilars face intense price competition and erosion once multiple entrants reach a market, which can pressure revenue and margins. Regulatory timing is uncertain, and a complete response letter or delay on any pending BLA would push out revenue. The year-over-year decline in first-half revenue highlights the lumpiness of milestone-driven results. Alvotech also raised capital in mid-2026, and further financing could dilute holders. Manufacturing, interchangeability standards and Patent litigation remain persistent industry risks.

Conclusion

Alvotech heads into the back half of 2026 with a widening biosimilar pipeline, fresh partnerships with Teva and Lotus, and a guidance framework that leans on a stronger finish to the year. The steady share price masks a busy regulatory calendar, with FDA decisions on AVT05 and AVT06 and momentum on the AVT80 Entyvio filing all in play. Investors may be watching those approvals, Partnership execution and delivery against full-year targets as the developments most likely to break the deadlock in ALVO.